IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma

IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma

Glioma is characterized by strong immunosuppression and excessive angiogenesis. Based on existing reports, it can be speculated that the resistance to anti-angiogenic drug vascular endothelial growth factor A (VEGFA) antibody correlates to the induction of novel immune checkpoint indoleamine 2,3-dio...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Zikang Xing, Xuewen Li, Zhen Ning Tony He, Xin Fang, Heng Liang, Chunxiang Kuang, Aiying Li, Qing Yang
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: MDPI AG 2024-06-01
Sarja:Pharmaceutics
Aiheet:
glioma
angiogenesis
indoleamine 2,3-dioxygenase 1
tryptophan depletion
general control nonderepressible 2
Linkit:https://www.mdpi.com/1999-4923/16/7/870

Internet

https://www.mdpi.com/1999-4923/16/7/870

Samankaltaisia teoksia